1. Gopal, A.D., Wallach, J.D., Aminawung, J., Gonsalves, G., Dal-Re, R. Miller, J.E.,and Ross, J.S, (2018) Adherence to ICMJE Prospective Registration Policy and Implications for Endpoint Integrity: A Cross-Sectional Analysis of Trials Published in High-Impact Specialty Society Journals, Trials.
  2. Miller, J.E. (2018) Transparency and Data-sharing in Clinical Research and the Pharma Industry (accepted, special compendium edited by Harvard University Law)
  3. Wallach JD, Egilman AC, Dhruva SS, McCarthy ME, Miller J.E., Woloshin S, Schwartz LM, Ross JS (2018), Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis. BMJ. 2018 May 24; 2018 May 24. PMID: 29794072
  4. Puthumana, J., Miller, J.E., Kim, J., and Ross, J., (2018) Availability of Novel Therapeutic Agents through Expanded Access and Compassionate Use Programs, JAMA Network Open. 2018;1(2):e180283. 
  5. Qunaj L, Jain RH, Atoria CL, Gennarelli RL, Miller JE, Bach PB.(2018), Delays in the Publication of Important Clinical Trial Findings in Oncology, JAMA Oncol. 2018 Apr 12:e180264. doi: 10.1001/jamaoncol.2018.0264. 
  6. Zou, C.X.,Becker, J.E., Phillips, A.T., Krumholz, H.M.,Miller, J.E.,and Ross, J.S. (2018) Impact of FDAAA on Registration, Results Reporting and Publication of Clinical Trials Supporting FDA Approval of Neuropsychiatric Drugs, JAMA Research Letter. 10.1186/s13063-017-2068-3
  7. Miller, J.E.(2018). Big Data Probably Knows More About You Than Your Friends Do, Leaps Magazine, February 5, 2018. 
  8. Miller, J.E., Wilenzick, M, Ritcey, N., Ross, J., Mello, M. (2017) Measuring Clinical Trial Transparency: An Empirical Analysis of Newly Approved Drugs BMJ Open: e017917. doi:10.1136/ bmjopen-2017-017917 
  9. Phillips, A.T., Desai, N.R., Krumholz, H.M., Zou, C.X., Miller, J.E., and Ross, J.S, (2017), Association of the FDA Amendment Act with trial registration, publication, and outcome reporting, Trials. 2017 Jul 18;18(1):333. doi: 10.1186/s13063-017-2068-3.
  10. Miller, J.E., Mello, M.M., Korn, D., Ross, J.S.(2017) Letter In Reply:  Clinical Trial Transparency: A re-assessment of industry compliance with clinical trial registration and reporting requirements in the United States, BMJ Open, 7.
  11. Miller, J.E., Ross, J.S., Moch, K.I.; Caplan, A.L. (2017). Characterizing Expanded Access and Compassionate Use Programs for Experimental Drugs, BMC Res Notes, 10 (1):350. doi: 10.1186/s13104-017-2687-5 
  12. Benston, S., Ritcey, N., Miller, J.E.(2017). Authority and Ambiguity: The Complex History of, and Current Challenges to, U.S. Administrative Agencies’ Rulemaking Power, NYSBAHealth Law Journal, 22 (2): 45-53.
  13. Loike, J.D. and Miller, J.E. (2017). The Hidden Costs of New Drugs: Improving FDA Evaluations Without Jeopardizing Safety and Efficacy, The Scientist.
  14. Miller, J.E. (2016). Transparency and Trustworthiness in Healthcare Innovation, Healthcare Innovation, Health Policy Publishing.
  15. Miller, J.E. (2016). How full disclosure of clinical trial data will benefit the pharmaceutical industry, The Pharmaceutical Journal, 295:7890.
  16. Miller, J., Caplan, A., and Blasimme, A. (2016). Designing Clinical Trials for New Drugs: Ethics, Governance, and Reputational Challenges. Clinical Researcher, 30(1), 34-39. 
  17. Li, R. H., Wacholtz, M. C., Barnes, M., Boggs, L., Callery-D'Amico, S., Davis, A., Digilova, A., Forster, D., Heffernan, K., Luthin, M., Lynch, H. F., McNair, L., Miller, J. E., Murphy, J., Van Campen, L., Wilenzick, M., Wolf, D., Woolston, C., Aldinger, C., Bierer, B. E. (2016). Incorporating Ethical Principles into Clinical Research Protocols: A tool for protocol writers and ethics committees. Journal of Medical Ethics. 
  18. Miller, J.E., Korn, D., and Ross, J. (2015). Clinical Trial Registration, Reporting, Publication and FDAAA Compliance: A cross-sectional analysis and ranking of new drugs approved by the FDA in 2012. BMJ Open, 5 (e009758).  
  19. Miller, J.E. (2015). Developing Drugs Differently. Health Affairs, 34 (12):2202.
  20. Welch, M.J, Lally, R., Miller, J.E., Pittman, S., Brodsky, L., Caplan, A., Uhlenbrauck, G., Louzao, D.M., Fischer, J.H., and Wilfond, B. (2015). The Ethics and Regulatory Landscape of Including Vulnerable Populations in Pragmatic Clinical Trials. Clinical Trials, 12(5):503-10. 
  21. Whicher, D.M., Miller, J.E., Dunham, K.M., and Joffe, S. (2015). Gatekeepers for Pragmatic Clinical Trials. Clinical Trials, 12 (5):442-8. 
  22. Miller, J.E. (2015). Behavioural Economics and Global Bioethics. H. ten Have (Ed.), Encyclopaedia of Global Bioethics. Springer.
  23. Miller, J.E. (2015). Certification and Corporate Reputation. Craig Carroll (Ed.), Encyclopaedia of Corporate Reputation. Sage Publications, Inc.
  24. Miller, J.E. (2015). Corruption and Bioethics, In H. ten Have (Ed), Encyclopedia of Global Bioethics, Springer.Loike, J. and
  25. Miller, J.E. (2015). Restoring Trust, Mission and Ethics in the Pharma Industry, BrinkNews, Atlantic Media.
  26. Miller, J.E. (2015). Bioethical Standards in the Pharmaceutical Industry? A proposal for how to marry theory with praxis. IF Press.
  27. Miller, J.E. (2014). Translational Biotechnology. The Scientist.
  28. Miller, J.E. & Loike, J. (2014). The Ethics of Personalized Medicine, Bioethics, 4th Edition. Edited by Bruce Jennings. Farmington Hills, MI: Macmillan Reference USA.
  29. Miller, J.E. (2013). How a Clinical Trial Registry Became a Symbol of Misinformation. Hastings Center Report, 43 (6), 11-12.
  30. Miller, J.E. (2013). Bioethical Accreditation or Rating Needed to Restore Trust in Pharma. Nature Medicine, 19 (3), 261.
  31. Miller, J.E. (2013). From Bad Pharma to Good Pharma: Aligning Market Forces with Good and Trustworthy Practices through Accreditation, Certification and Rating. Journal of Law, Medicine, and Ethics, 41 (3), 601-610.
  32. Miller, J.E. & English, W. (2013). Corruption and Bioethics. In B. Gordijn, & H. ten Have (Eds.), Handbook of Global Bioethics. Springer, 599-618.
  33. Miller, J E. (2013). Rebuilding Trust and Effectively Communicating Ethics Efforts. About Pharma and Medical Devices.
  34. Miller, J.E. (2013). On Restoring Trust and Ethics in Pharma, Edmond J. Safra Center for Ethics E-Book, Harvard University.
  35. Miller, J.E. (2012). Irreligious Bioethics, Nonsense on Stilts? The American Journal of Bioethics, 12 (12), 15-17.
  36. Miller, J.E. & Loike, J. (2012). BioCEP: A Model Educational Program for Cross-cultural Bioethics. Cambridge Quarterly of Healthcare Ethics, 21 (3), 409-416.
  37. Antommaria, A.H., Powell, T., Miller, J.E., Christian, M., & for the Task Force for Pediatric Emergency Mass Critical Care. (2011). Ethical Issues in Pediatric Emergency Mass Critical Care. Pediatric Critical Care Medicine, 12 (6 Suppl), 163-8.
  38. Miller, J.E. (2010). Pandemic Influenza Triage in the Clinical Setting. Prehospital and Disaster Medicine, 25 (2), 105-6.
  39. Miller, J.E. (October 1, 2008). Pfizer’s Stem Cell Ventures, Eli Lilly’s DR Payment Disclosures, & the Supreme Court Case Wyeth v. Levine’s Preemption Temptation, Biotech-Now, Biotechnology Industry Organization, Washington, DC.
  40. Miller, J.E. (June 20, 2008). Globalization in Biotechnology, Biotech-Now, Biotechnology Industry Organization, California.
  41. Miller, J.E. (June 19, 2008). Ernst & Young 2008 Global Biotechnology Report, Trends Summary: R&D productivity, personalized medicine and globalization, Biotech-Now, Biotechnology Industry Organization, California.


Jennifer E. Miller, PhD

Bioethics. Governance. Data. Health